Mårtensson G, Sörenson S
Department of Pulmonary Medicine, Renströmska Hospital, University of Göteborg, Sweden.
Cancer Chemother Pharmacol. 1989;24(2):133-4. doi: 10.1007/BF00263135.
A total of 23 consecutive, previously untreated patients with radiographically evaluable, malignant pleural mesothelioma were treated in a phase II study with vincristine. Vincristine was given i.v. at a dose of 1.3 mg/m2 once weekly for 4 weeks, then every 2 weeks. No response was observed. The result suggests that vincristine has little or no therapeutic value in the treatment of malignant mesothelioma.
